{"id":62113,"date":"2025-10-30T07:02:51","date_gmt":"2025-10-30T06:02:51","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/"},"modified":"2025-10-30T07:02:51","modified_gmt":"2025-10-30T06:02:51","slug":"rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/","title":{"rendered":"Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in Riyadh"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nSVAX will support Rubedo\u2019s regulatory filings and conduct of Phase 2 clinical trials for lead program, RLS-1496, in the Kingdom of Saudi Arabia and the Emirate of Dubai<\/li>\n<li>\nPartnership builds Rubedo\u2019s footprint as a Hevolution portfolio company and reflects the growing strategic importance of the region in healthy longevity research and the life sciences<\/li>\n<\/ul>\n<p>SAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/GHE25?src=hash\" target=\"_blank\">#GHE25<\/a>&#8211;Rubedo Life Sciences, Inc. (Rubedo), a leading AI-driven, clinical-stage biotech specializing in selective cellular rejuvenation medicines, today announced a strategic partnership with SVAX during the Future Investment Initiative (FII) week in Riyadh. This collaboration will focus on advancing RLS-1946, Rubedo\u2019s promising lead candidate, through Phase 2 clinical trials in the Kingdom of Saud Arabia and the Emirate of Dubai.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20251029971777\/en\/2625999\/5\/a979b361-f9ef-4717-8641-e5c0b8fc834b.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251029971777\/en\/2625999\/22\/a979b361-f9ef-4717-8641-e5c0b8fc834b.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251029971777\/en\/2625999\/5\/a979b361-f9ef-4717-8641-e5c0b8fc834b.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251029971777\/en\/2625999\/21\/a979b361-f9ef-4717-8641-e5c0b8fc834b.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251029971777\/en\/2624968\/5\/Rubedo_Logo_Vector_CMYK_1.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251029971777\/en\/2624968\/22\/Rubedo_Logo_Vector_CMYK_1.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251029971777\/en\/2624968\/5\/Rubedo_Logo_Vector_CMYK_1.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251029971777\/en\/2624968\/21\/Rubedo_Logo_Vector_CMYK_1.jpg\"><\/a><\/p>\n<p>\nExpanded Details<\/p>\n<p>\nStrategic Footprint Expansion: The partnership underscores Rubedo\u2019s integration into Hevolution\u2019s portfolio, highlighting the region\u2019s strategic importance in healthspan research and the life sciences.<\/p>\n<p>\nKey Collaborators: SVAX, a leading Saudi vaccine and biologics manufacturer and clinical research organization (CRO), in conjunction with Fakeeh Care Group, will facilitate regulatory filings and clinical trial conduct, boosting Rubedo\u2019s clinical capabilities in the GCC region. SVAX will support Rubedo\u2019s regulatory filings in Saudi Arabia and the conduct of its planned Phase 2 Atopic Dermatitis clinical trial in the Kingdom and the Emirate of Dubai.<\/p>\n<p>\nThis announcement comes on the heels of the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20250917407244%2Fen%2FRubedo-Life-Sciences-Announces-U.S.-FDA-Clearance-of-IND-for-Selective-GPX4-Modulating-Lead-Drug-Candidate-RLS-1496-for-Actinic-Keratosis-Expands-Clinical-Advisory-Board&amp;esheet=54348031&amp;newsitemid=20251029971777&amp;lan=en-US&amp;anchor=U.S.+FDA+clearance+of+the+Investigational+New+Drug+%28IND%29+application&amp;index=1&amp;md5=8b81bedea59f833396cc73be2395597e\" rel=\"nofollow\" shape=\"rect\">U.S. FDA clearance of the Investigational New Drug (IND) application<\/a> for a Phase 1b\/2a study with lead drug candidate RLS-1496 in patients with actinic keratosis. The Gulf Cooperation Council (GCC) study is expected to begin in Q2 2026.<\/p>\n<p>\n\u201cIn our earliest meetings with the Hevolution team, we were convinced that Saudi Arabia and the GCC had the potential to play a leading role in healthy longevity science,\u201d said Rubedo CBO Ali Siam. \u201cThis partnership with SVAX will translate this vision into reality by partnering with one of the leading pillars of the Saudi Vision 2030 National Biotech Strategy. We were honored to be joined in the signing ceremony by our new partner, Prof. Mazen Hassanain, Managing Director and CEO of SVAX, and Hevolution Foundation SVP of Research, HRH Princess Dr. Haya Bint Khaled Bin Bandar Al Saud, a leading voice of healthspan and healthy longevity both globally and in the Kingdom.\u201d<\/p>\n<p>\nProf. Mazen Hassanain, Managing Director and CEO of SVAX said, \u201cWe are thrilled to be working with the Rubedo team to bring this innovative therapy to Saudi Arabia, particularly when conditions like Atopic Dermatitis and Vitiligo are such high areas of unmet need in our region. Ali and I had been discussing our shared vision for catalyzing high science in the Kingdom, and as the pieces of the Saudi National Biotech Strategy came together, this became a clear win.\u201d<\/p>\n<p>\n\u201cAs a truly global longevity therapeutics company, we are thrilled to be partnering with SVAX to incorporate patient populations that have historically been underrepresented in clinical trials &#8211; particularly in Atopic Dermatitis,\u201d said Rubedo CEO, Dr. Frederick Beddingfield. \u201cThis disease has a significant treatment burden in Saudi Arabia &#8211; studies have found the prevalence as high as 30%<sup>1<\/sup> of the adult population &#8211; and we know from published studies and meta-analyses that this disease presents differently across ethnicities<sup>2<\/sup> and that this has been an ongoing challenge in the standard of care worldwide. Incorporating study sites at the crossroads of three continents will help provide a more representative overall patient population for the evaluation of RLS-1496 in this important condition.\u201d<\/p>\n<p>\n\u201cAt Hevolution, we\u2019re driving global advancements in healthspan science. We\u2019re thrilled by Rubedo Life Science\u2019s pivotal step with RLS-1946 entering Phase 2 trials. Teaming up with SVAX for this GCC trial underscores our region\u2019s rapid growth in clinical research capabilities and our commitment to elevating healthspan science capability and capacity in Saudi Arabia. This collaboration is set to revolutionize geroscience and fortify the regional biotech landscape,\u201d said Hevolution SVP of Research HRH Princess Dr. Haya Bint Khaled bin Bandar Al Saud.<\/p>\n<p>\n<b>About RLS-1496 and GPX4 Modulation<\/b><\/p>\n<p>\nRubedo\u2019s lead candidate RLS-1496, being developed for topical and oral administration, is a first-in-class, potentially disease-modifying selective GPX4 modulator targeting pathologic senescent or \u201caged\u201d cells that drive chronic degenerative diseases and conditions associated with biological aging processes. These include immunology and inflammation (I&amp;I), dermatology and skin aging, metabolic syndrome (obesity, diabetes, liver fibrosis), sarcopenia, and neurodegenerative disease. In certain pathologic cells, aging is associated with an imbalance in GPX4. Modulation of GPX4 sensitizes cells to ferroptosis, which is a type of programmed cell death and is believed to be an achilles heel of senescent \u201czombie\u201d cells. By modulating GPX4 in ferroptosis-sensitive senescent \u201caged\u201d cells, RLS-1496 may be able to clear these cells to not only fight disease, but also support healthy cells to function properly and restore tissue homeostasis.<\/p>\n<p>\n<b>About Rubedo Life Sciences<\/b><\/p>\n<p>\nRubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC\u2122 drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders. Our lead drug candidate \u2013 RLS-1496, a potential first-in-class disease-modifying selective GPX4 modulator \u2013 is currently in Phase I clinical trials. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Mountain View, CA, USA, and has offices in Milan, Italy. For additional information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rubedolife.com&amp;esheet=54348031&amp;newsitemid=20251029971777&amp;lan=en-US&amp;anchor=www.rubedolife.com&amp;index=2&amp;md5=186df35629770af3e4709b9582f59b8b\" rel=\"nofollow\" shape=\"rect\">www.rubedolife.com<\/a>.<\/p>\n<p>\n<b>About Hevolution Foundation<\/b><\/p>\n<p>\nEstablished by Royal Order in 2018 and launched in 2021, Hevolution Foundation is a first-of-its kind global non-profit organization that incentives grants and early-stage investments to accelerate independent research and entrepreneurship in the emerging field of healthspan science. With a focus on aging as a treatable process, Hevolution aims to propel aging and geroscience research forward and support a cutting-edge global ecosystem of talent. Headquartered in Riyadh, Saudi Arabia, with a North American hub in Boston and plans for further international expansion, the Foundation has set key goals and targets to advance its Vision &amp; Mission. Over the last three years, Hevolution has allocated over $400M in funding.<\/p>\n<p>\n<sup>1<\/sup> ZahrAllayali <i>et al.<\/i> The Prevalence, Knowledge and Attitude Regarding Atopic Dermatitis among Adult Population in Saudi Arabia. Dermatology and Dermatitis, 2024 Nov;9(7):01-11 DOI:10.31579\/2578-8949\/152 <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.31579%2F2578-8949%2F152&amp;esheet=54348031&amp;newsitemid=20251029971777&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdoi.org%2F10.31579%2F2578-8949%2F152&amp;index=3&amp;md5=b7342dc4ae17f1daa4c21420ee0ee9b3\" rel=\"nofollow\" shape=\"rect\">https:\/\/doi.org\/10.31579\/2578-8949\/152<\/a><\/p>\n<p>\n<sup>2<\/sup> Brunner PM, Guttman-Yassky E. Racial differences in atopic dermatitis. Ann Allergy Asthma Immunol. 2019 May;122(5):449-455. doi: 10.1016\/j.anai.2018.11.015. Epub 2018 Nov 20. PMID: 30465859.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b><span class=\"bwuline\">Investor Contact:<\/span><\/b><br \/>Rubedo CBO Ali Siam<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#x69;&#x6c;&#116;&#x6f;&#58;a&#x6c;&#105;s&#x69;&#97;m&#x40;&#114;u&#x62;&#101;&#x64;&#x6f;&#108;&#x69;&#x66;&#101;&#x2e;&#99;o&#x6d;\" rel=\"nofollow\" shape=\"rect\">alisiam&#64;rubedolife&#46;com<\/a><br \/>781-974-9559<\/p>\n<p>\n<b><span class=\"bwuline\">Media Contact:<\/span><\/b><br \/>Peter Collins<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;&#x74;o&#58;&#112;&#x2e;&#x63;o&#108;&#108;&#x69;&#x6e;s&#64;&#116;&#x6f;&#x67;&#x6f;r&#117;&#x6e;&#x2e;&#x63;o&#109;\" rel=\"nofollow\" shape=\"rect\">p&#46;&#99;&#111;&#x6c;&#x6c;&#x69;&#x6e;s&#64;&#116;&#111;&#x67;&#x6f;&#x72;&#x75;n&#46;&#99;&#111;&#109;<\/a><br \/>908-499-1200<\/p>\n<p>\nHevolution Media contact<br \/>\n<br \/>Mishal Almubarak<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#116;&#111;:me&#x64;&#x69;&#x61;&#x40;&#104;&#101;vol&#x75;&#x74;&#x69;&#x6f;&#110;&#46;&#99;om\" rel=\"nofollow\" shape=\"rect\">&#x6d;&#x65;&#x64;&#105;&#97;&#64;he&#x76;&#x6f;&#x6c;&#x75;&#116;&#105;on&#x2e;&#x63;&#x6f;&#x6d;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SVAX will support Rubedo\u2019s regulatory filings and conduct of Phase 2 clinical trials for lead program, RLS-1496, in the Kingdom of Saudi Arabia and the Emirate of Dubai Partnership builds Rubedo\u2019s footprint as a Hevolution portfolio company and reflects the growing strategic importance of the region in healthy longevity research and the life sciences SAN &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62113","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in Riyadh - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in Riyadh - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SVAX will support Rubedo\u2019s regulatory filings and conduct of Phase 2 clinical trials for lead program, RLS-1496, in the Kingdom of Saudi Arabia and the Emirate of Dubai Partnership builds Rubedo\u2019s footprint as a Hevolution portfolio company and reflects the growing strategic importance of the region in healthy longevity research and the life sciences SAN ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-30T06:02:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251029971777\/en\/2625999\/22\/a979b361-f9ef-4717-8641-e5c0b8fc834b.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in Riyadh\",\"datePublished\":\"2025-10-30T06:02:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\\\/\"},\"wordCount\":1137,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251029971777\\\/en\\\/2625999\\\/22\\\/a979b361-f9ef-4717-8641-e5c0b8fc834b.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\\\/\",\"name\":\"Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in Riyadh - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251029971777\\\/en\\\/2625999\\\/22\\\/a979b361-f9ef-4717-8641-e5c0b8fc834b.jpg\",\"datePublished\":\"2025-10-30T06:02:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251029971777\\\/en\\\/2625999\\\/22\\\/a979b361-f9ef-4717-8641-e5c0b8fc834b.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251029971777\\\/en\\\/2625999\\\/22\\\/a979b361-f9ef-4717-8641-e5c0b8fc834b.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in Riyadh\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in Riyadh - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/","og_locale":"en_US","og_type":"article","og_title":"Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in Riyadh - Pharma Trend","og_description":"SVAX will support Rubedo\u2019s regulatory filings and conduct of Phase 2 clinical trials for lead program, RLS-1496, in the Kingdom of Saudi Arabia and the Emirate of Dubai Partnership builds Rubedo\u2019s footprint as a Hevolution portfolio company and reflects the growing strategic importance of the region in healthy longevity research and the life sciences SAN ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/","og_site_name":"Pharma Trend","article_published_time":"2025-10-30T06:02:51+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251029971777\/en\/2625999\/22\/a979b361-f9ef-4717-8641-e5c0b8fc834b.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in Riyadh","datePublished":"2025-10-30T06:02:51+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/"},"wordCount":1137,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251029971777\/en\/2625999\/22\/a979b361-f9ef-4717-8641-e5c0b8fc834b.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/","url":"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/","name":"Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in Riyadh - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251029971777\/en\/2625999\/22\/a979b361-f9ef-4717-8641-e5c0b8fc834b.jpg","datePublished":"2025-10-30T06:02:51+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251029971777\/en\/2625999\/22\/a979b361-f9ef-4717-8641-e5c0b8fc834b.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251029971777\/en\/2625999\/22\/a979b361-f9ef-4717-8641-e5c0b8fc834b.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in Riyadh"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62113"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62113\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62113"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62113"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}